PEDIATRICS Vol. 81 No. 1 January 1988, pp. 166-168
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by COCHI, S. L.
Right arrow Articles by PREBLUD, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by COCHI, S. L.
Right arrow Articles by PREBLUD, S. R.

Progress in Haemophilus Type b Polysaccharide Vaccine Use in the United States

STEPHEN L. COCHI MD1, DENNIS O'MARA BS1, and STEPHEN R. PREBLUD MD1

1 Division of Immunization Centers for Disease Control, Atlanta

In April 1985, the US FDA licensed Haemophilus influenzae type b polysaccharide vaccine to protect against invasive disease caused by H influenzae type b. Shortly thereafter, both the Immunization Practices Advisory Committee of the US Public Health Service1 and the Committee on Infectious Diseases of the American Academy of Pediatrics2 published recommendations for the routine use of this new vaccine in children at 24 months of age. More recently, updates of these recommendations have been published.3-5

From the date of vaccine licensure through July 1986, when the survey by Gururaj et al6 was conducted, more than 5 million doses of vaccine were distributed in the United States.




This article has been cited by other articles:


Home page
 ScienceHome page
V. Verez-Bencomo, V. Fernandez-Santana, E. Hardy, M. E. Toledo, M. C. Rodriguez, L. Heynngnezz, A. Rodriguez, A. Baly, L. Herrera, M. Izquierdo, et al.
A Synthetic Conjugate Polysaccharide Vaccine Against Haemophilus influenzae Type b
Science, July 23, 2004; 305(5683): 522 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
H. Peltola
Worldwide Haemophilus influenzae Type b Disease at the Beginning of the 21st Century: Global Analysis of the Disease Burden 25 Years after the Use of the Polysaccharide Vaccine and a Decade after the Advent of Conjugates
Clin. Microbiol. Rev., April 1, 2000; 13(2): 302 - 317.
[Abstract] [Full Text] [PDF]